Teva Pharmaceutical Industries Ltd. (TEVA) announced the China National Medical Products Administration has approved AUSTEDO for the treatment of chorea associated with Huntington's disease and Tardive Dyskinesia in adults. The company will commercialize AUSTEDO in China independently.
Teva Pharma noted that this is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.
Gianfranco Nazzi, Executive Vice President, International Markets, at Teva, stated: "We look forward to bringing more of the essential medicines in our portfolio to patients in China, and to fuel organic growth and expand our presence in this important market."
For comments and feedback contact: editorial@rttnews.com
Business News